I found this but wouldnt know how long the clinical trials took...
"Neupro, with the active ingredient rotigotine, is a non-ergolinic dopamine receptor-agonist formulated as a transdermal delivery system, a patch, designed for once a day application and provides rotigotine continuously to the body for 24 hours. Multinational clinical studies in patients with early stage Parkinson's disease were completed at the end of 2003"
So Clinical trial ended at the end of 2003 and FDA approval in May 2007... 3 and a half years .. but again i dont know much about the processes so your interpretation is welcome...
- Forums
- ASX - By Stock
- WFL
- shareholder update
shareholder update, page-113
-
- There are more pages in this discussion • 18 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add WFL (ASX) to my watchlist
|
|||||
Last
0.3¢ |
Change
0.000(0.00%) |
Mkt cap ! $1.478M |
Open | High | Low | Value | Volume |
0.0¢ | 0.0¢ | 0.0¢ | $0 | 0 |
Featured News
WFL (ASX) Chart |
Day chart unavailable